drugset / Trial / NCT01449747

Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

NCT01449747

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor

Timeline

Start
2011-12
Primary completion
2014-08
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sitagliptin Small molecule 100 mg Oral